AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03885388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: multicourse methotrexate chemotherapy
Study NCT03885388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX+ACTD
Description: combination use of methotrexate and actinomycin
Study NCT02234180 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT02234180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study NCT00746161 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reconstruction after total gastrectomy
Description: Roux-en-Y
Study NCT00746161 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstruction after total gastrectomy
Description: double tract reconstruction
Study NCT00815737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhubarb
Description: 14 days of rhubarb
Study NCT00815737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 14 days of Placebo
Study NCT00848315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention
Description: The intervention emphasizes patients' ethnic preferences and traditions (e.g., adapting ethnic recipes to meet dietary goals) and the use of available community resources (e.g., available areas for exercise), and is delivered utilizing strategies and materials appropriate for low-literate/illiterate patients.
Study NCT02112591 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transobturator subtrigonal tape S-TOT
Description: Minimally invasive surgery for placement of suburethral polypropylene tape (TOT), which is widely used around the world and considered the standard of treatment at present, has very limited efficacy when considering the correction of SUI without affecting normal micturition. There is evidence that the placement of autologous fascia tape in subtrigonal position has higher efficacy. Thus, the subtrigonal placement of polypropylene mesh tape through minimally invasive procedures could have higher efficacy.
Study NCT02112591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transobturator suburethral tape (TOT)
Description: Minimally invasive procedures in which needles are inserted via transobturator approach for the placement in mid-urethral position of polypropylene tape that is 1.5cm wide for the treatment of SUI
Study NCT04120324 — intervention group
Intervention type: OTHER
Intervention: Eligible for Same Day Discharge
Description: Preoperative Physiotherapy and Anesthesia Criteria met.
Study NCT04120324 — intervention group
Intervention type: PROCEDURE
Intervention: Primary Single Joint Total Hip Arthroplasty
Description: Total Hip Replacement Surgery
Study NCT04120324 — intervention group
Intervention type: OTHER
Intervention: Discharge Same Day
Description: Postoperative criteria for Same Day Discharge met.
Study NCT01635140 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
Study NCT01635140 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Conventional arm
Description: A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.
Study NCT04051580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer
Description: Comparison of Lactated Ringer's Solution and PlasmaLyte-A as a Base Solution for Del Nido Cardioplegia
Study NCT04051580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer
Description: Comparison of Lactated Ringer's Solution and PlasmaLyte-A as a Base Solution for Del Nido Cardioplegia
Study NCT00407667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial galvanic stimulation
Description: for tDCS: Siemens Universal-Neuroton 826 for arm training: Bi-Manu-Track, Reha-Stim, Berlin
Study NCT00407667 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial galvanic stimulation
Description: for tDCS: Siemens Universal-Neuroton 826 for arm training: Bi-Manu-Track, Reha-Stim, Berlin
Study NCT03608969 — intervention group
Intervention type: OTHER
Intervention: NOT-S
Description: Participants are assessed for the orofacial function using the Nordic Orofacial test- screening (NOT-S), Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS) and Communication Function Scale (CFS). Oral health related quality of life is assessed using the Parental- Caregiver Perceptions Questionnaire (P-CPQ). Caries experience was measured by identifying decayed, missing, and filled teeth for deciduous and permanent teeth (dmft). Gingival index and type of occlusion will be recorded.
Study NCT00940173 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DIABECELL(R)
Description: 10,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
Study NCT00940173 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DIABECELL(R)
Description: 15,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
Study NCT00940173 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DIABECELL(R)
Description: 20,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
Study NCT00940173 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DIABECELL(R)
Description: 5,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
Study NCT02080078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Study NCT02080078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study NCT02421510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: High dose Sotagliflozin, once daily, before the first meal of the day
Study NCT02421510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Low dose Sotagliflozin,once daily, before the first meal of the day
Study NCT02421510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily, before the first meal of the day
Study NCT02448043 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bimatoprost 0.01%
Description: Bimatoprost drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days
Study NCT02448043 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo: saline
Description: Placebo drops added to the proximal nail folds of the hand digits opposite the study hand two times per day for 30 days
Study NCT01138046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib in combination with weekly paclitaxel
Description: These subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle) plus lapatinib (1500 mg once daily, starting on the second day of phase I). Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Study completion is defined as deaths after administering study treatment for more than once. Subjects will be treated with paclitaxel for standard of 6 cycles, and may be continued at the discretion of investigators. If the subject experiences progression, an unacceptable toxicity related to paclitaxel, or termination of lapatinib therapy, paclitaxel therapy must be terminated any time of study period, even before 6 cycles of paclitaxel are given.
Study NCT00850642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190195 100mg
Description: GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
Study NCT00850642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo :~2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10)
Study NCT00827242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following a 4-week placebo lead-in period, subjects received placebo tablet by mouth once daily over a 12-week period.
Study NCT00827242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: Following a 4-week placebo lead-in period, subjects received tadalafil 5 mg tablet by mouth once daily over a 12-week period.
Study NCT02650557 — intervention group
Intervention type: PROCEDURE
Intervention: angiography
Description: angiography or arteriography is a medical imaging technique used to visualize the inside, or lumen, of blood vessels and organs of the body, with particular interest in the arteries, veins, and the heart chambers. This is traditionally done by injecting a radio-opaque contrast agent into the blood vessel and imaging using X-ray based techniques such as fluoroscopy.
Study NCT03637374 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Visceral Manifold and Thoracic Bifurcation
Description: Endovascular stent graft system
Study NCT02316275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No post-operative activity restrictions
Description: Patients are to resume regular activity immediately after mid-urethral sling surgery. The investigators will determine the impact of unrestricted post-operative activity on continence outcomes of mid-urethral sling surgery in women with stress urinary incontinence (SUI). Investigators will measure the effect of unrestricted post-operative activity on early health-related quality of life (HRQOL). A Productivity Loss form for cost-effective analysis will be asked of the patient.
Study NCT02316275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard post-operative activity restriction
Study NCT04478643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic: Lactobacillus Reuteri
Description: Lactobacillus reuteri ATCC PTA 5289 (a minimum of 2 × 108 colony-forming units L. reuteri Prodentis/lozenge, BioGaia AB)
Study NCT04478643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo lozenge. Will be identical in taste, texture and appearance to the Probiotic one.
Study NCT03637374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visceral Manifold and Thoracic Bifurcation
Description: Endovascular stent graft system
Study NCT03637374 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Unitary Manifold
Description: Endovascular stent graft system
Study NCT03637374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unitary Manifold
Description: Endovascular stent graft system
Study NCT03637374 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TAAA Debranching Stent Graft System
Description: Endovascular stent graft system
Study NCT01158183 — intervention group
Intervention type: DRUG
Intervention: BAY86-5046_Interferon-beta-1b
Description: Electronic questionnaires
Study NCT03637374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAAA Debranching Stent Graft System
Description: Endovascular stent graft system
Study NCT03595891 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT03947723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid). A corneal shield will be placed into the fornix prior to treatment. Each section will be treated with the designated power setting in the following manner. The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm. The designated power will be applied for 1 second. All lashes in each segment will be treated. The segments will then be excised and placed into labelled and coded containers of formalin.
Study NCT03503123 — intervention group
Intervention type: DEVICE
Intervention: Monitoring physiology with Electrical Impedance Tomography, Electromyography and transcutaneous carbon dioxide measurements.
Description: Both groups get the same exposures: with measure physiology in both groups by using non-invasive measurement techniques. The techniques we use are Electrical Impedance Tomography to determine degree of hyperinflation. We use Electromyography to analyse respiratory drive. We measure transcutaneous carbon dioxide to assess the effects of non-invasive ventilation. Thereby, we will perform lung function tests.
Study NCT02828267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Negotiational Intervention
Description: This is a 5-10 minute conversation using the principles of motivational interviewing between the healthcare practioner and the patient to motivate the patient to identify at risk alcohol use and through self-empowerment create a plan to decrease alcohol use.
Study NCT02828267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Negotiational Intervention
Description: This is a 5-10 minute conversation using the principles of motivational interviewing between the healthcare practioner and the patient to motivate the patient to identify at risk alcohol use and through self-empowerment create a plan to decrease alcohol use.
Study NCT02828267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Booster
Description: This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use.
Study NCT02828267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Booster
Description: This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use. Information in this text will be personalized based on the participants specific reasons for reducing their alcohol use rather than a standard text content.
Study NCT01403298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based HIV prevention
Description: This individual, family-based intervention provides sex and HIV/AIDS education as part of a family-based general health education program that focuses on safe decision-making and how to control emotions to stay safe and improve parenting skills.
Study NCT01403298 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adolescent Only Health Promotion
Description: An individual, adolescent-only health education program that focuses on risk behaviors related to HIV/AIDS, smoking, diet and exercise
Study NCT01727180 — intervention group
Intervention type: OTHER
Intervention: Questionnaire based on the McGill Pain Questionnaire
Description: Interview questionnaire based on the short form of the McGill Pain Questionnaire
Study NCT01104025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG, rabbit
Description: ATG, rabbit (Thymoglobulin, Genzyme) will be dosed at 5 mg/kg/dose, given IV on 5 consecutive days (titrated over 4 to 8 hours).
Study NCT01104025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be dosed at 150mg/m2, given IV. The first dose will be given 7 days (+/- 2 days) after the first dose of ATG, and be given weekly for a total of 7 doses.
Study NCT01104025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age\< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, >3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
Study NCT01104025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age\< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, >3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
Study NCT01104025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: will be started with the ATG. It will be divided BID, given IV for at least 1 week before switching to PO. Dosing: 20mg/m2/day x7days, 10mg/m2/day x7days, 5mg/m2/day x14days, 2.5mg/m2/day x14days, 1.25mg/m2/day x14days.
Study NCT01196572 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Urethrotomy
Description: surgical incision of urethral stricture using endoscopic cold knife vs. endoscopic laser
Study NCT01196572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal Urethrotomy
Description: surgical incision of urethral stricture using endoscopic cold knife vs. endoscopic laser
Study NCT03756441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: This intervention is a meditative practice which the individuals will practive in their daily life following the MBHP protocol
Study NCT03756441 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy group
Description: Caregivers will learn the technique of group problem solving
Study NCT04071652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mistral implantation
Description: Mistral implant is implanted in the Tricuspid valve
Study NCT02334644 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Formula (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)
Description: 2 sachets/day x 12 weeks
Study NCT02334644 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 sachets/day x 12 weeks
Study NCT02380560 — intervention group
Intervention type: DEVICE
Intervention: Ultrasonographic examination
Description: An abdominal ultrasound for: Estimation of gestational age, biophysical profile (BPP), Detection of any fetal gross anomalies, Assessment of fetal growth measurement of the Amniotic Fluid Index (AFI), Detection of any abnormal placental insertion and/or uterine structural abnormalities as septate or bicornuate uterus, measuring The myometrial thickness at 4 different sites:~a) The lower uterine segment (LUS): 2cm above the reflection of the full urinary bladder (b)The anterior wall: 1cm above the maternal umbilicus. (c)Fundus: by placing the scan probe perpendicularly above the uterine fundus so that the entire curvature of the uterus is visualized.~(d)The posterior wall: through using the maternal abdominal aortic pulsation as an anatomic marker.
Study NCT01762605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Study NCT01762605 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cast
Study NCT01136382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: pMDI, inhalation, bid, 6 weeks
Study NCT01136382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: pMDI, inhalation, bid, 6 weeks
Study NCT02778321 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Uses of SpiderFlash monitor
Description: Investigators will use the SpiderFlash®, Holter monitor (technology Secure Data) to have a storage capacity enabling a registration up to 30 days with sufficient autonomy.~The data collected :~* Demographic data: age, sex, vascular risk factors, antithrombotic therapy at the entrance, history of Transient Ischemic Accident (TIA) or Cerebral infarct (CI)~* Data on the CI:~* Monitoring Results scope ICU Neurovascular.~* Presence palpitations~* Treatment influencing the rate (beta-blockers or antiarrhythmic)~* Data on cardiac monitoring:~A questionnaire evaluating the safety of SpiderFlash® will be given to the patient and the results of Holter will be communicated at the end of the recording to the blinded rhythm specialist
Study NCT01771939 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 25-G vitrectomy and phacoemulsification
Description: 25-G vitrectomy with Internal Limiting Membrane peeling and phacoemulsification (cataract intervention)
Study NCT01771939 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification (cataract surgery)
Description: lens extraction after phacoemulsification and intra-ocular artificial lens implantation
Study NCT02963259 — intervention group
Intervention type: DEVICE
Intervention: SJM Infinity™ DBS IPG or SJM Brio™ DBS IPG system
Description: Implanted Medtronic® IPG will be explanted and replaced by a SJM Infinity™ DBS IPG or a SJM Brio™ DBS IPG system
Study NCT01827566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gluten
Study NCT01827566 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: gluten free flour
Study NCT02020915 — intervention group
Intervention type: PROCEDURE
Intervention: lateral sphincterotomy
Study NCT02020915 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasound guided lateral sphincterotomy
Study NCT03727620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin plus metronidazole
Description: patients were administered 250 mg of Flagyl and 500 mg of Dyspamox, three times a day for 7 days
Study NCT03727620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: patients were administered 200 mg of Longamycine the first day and 100 mg per day for 14 days
Study NCT04089917 — intervention group
Intervention type: DEVICE
Intervention: Q Aspiration Catheter
Description: The Q Aspiration Catheter is indicated for use in the removal of fresh, soft emboli and thrombi in the neurovascular system.